LEADER 04553nam  2201273z- 450 
001 9910557437003321
005 20231214133040.0
035   $a(CKB)5400000000043353
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69362
035   $a(EXLCZ)995400000000043353
100   $a20202105d2020      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aRadiopharmaceuticals for PET Imaging - Issue A
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020
215   $a1 electronic resource (212 p.)
311   $a3-03943-242-7 
311   $a3-03943-243-5 
330   $aPositron emission tomography (PET) is a very useful technique for medical diagnosis and drug development. Radiopharmaceuticals are a key element in PET techniques and one of the pivotal factors influencing the applications of PET. The aim of this Special Issue of Molecules is to report on the recent research work on a number of aspects of PET radiopharmaceuticals and their preclinical and clinical use. More specifically, the content of this Special Issue includes but is not limited to radiolabeling design, radiosynthesis, synthesis techniques, quality control methodologies, GMP production methods, product formulation, in vitro and in vivo preclinical PET evaluations, clinical evaluations, dosimetry, stability study and metabolite analysis, and modeling.
606   $aMedicine$2bicssc
610   $akinetic analysis
610   $aSiglec-9
610   $agallium-68
610   $avascular adhesion protein
610   $aVAP-1
610   $ainfection
610   $ainflammation
610   $aosteomyelitis
610   $aanimal model
610   $aStaphylococcus aureus
610   $amultiple myeloma
610   $apositron emission tomography/computed tomography
610   $aradiopharmaceuticals
610   $a18F-fluorodeoxyglucose
610   $atetrazine ligation
610   $aPET
610   $aSPECT
610   $aindium-11
610   $afluorine-18
610   $apositron emission tomography (PET), defluorination
610   $aisotopic exchange
610   $asilicon-based fluoride acceptor
610   $abioorthogonal chemistry
610   $atetrazine
610   $ainverse electron-demand Diels-Alder ligation
610   $aopioid
610   $analoxone
610   $aoverdose
610   $afentanyl
610   $acarfentanil
610   $a[11C]carfentanil
610   $apositron emission tomography
610   $areceptor occupancy
610   $apharmacokinetics
610   $a[18F]AlF
610   $aNOTA
610   $aNODAGA
610   $aPODS
610   $athiol-reactive
610   $alinker
610   $aaffibody molecule
610   $abioconjugation
610   $aEGFR
610   $atumor imaging
610   $avulnerable plaque
610   $amolecular imaging
610   $aPET imaging
610   $ananobody
610   $asingle-domain antibody
610   $asub-millimetre resolution
610   $aAlF-radiolabelling
610   $apreclinical radiopharmaceutical dosimetry
610   $aimage-based internal dosimetry
610   $aOLINDA
610   $aMCT1/MCT4 lactate transporter inhibitor
610   $a[18F]FACH
610   $aradiation safety
610   $asigma-1 receptor availability
610   $aorthotopic xenograft of glioblastoma in mouse
610   $asmall animal Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)
610   $a(S)-(?)-[18F]fluspidine
610   $aimaging-based biomarker
610   $aSV2A protein
610   $aPET radiotracers
610   $asynaptic loss
610   $aradiochemistry
610   $apreclinical development
610   $aclinical outcomes
610   $amonocarboxylate transporters (MCTs)
610   $aFACH
610   $a18F-labeled analog of FACH
610   $a?-CCA
610   $ablood-brain barrier (BBB)
610   $apositron emission tomography (PET) imaging
610   $apeptides
610   $aproteolysis
610   $ametabolic stability
615  7$aMedicine
700   $aRoivainen$b Anne$4edt$01323768
702   $aLi$b Xiang-Guo$4edt
702   $aRoivainen$b Anne$4oth
702   $aLi$b Xiang-Guo$4oth
906   $aBOOK
912   $a9910557437003321
996   $aRadiopharmaceuticals for PET Imaging - Issue A$93035833
997   $aUNINA